Haeberlein Samantha L. Budd Buys 12,000 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) Stock

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Director Haeberlein Samantha L. Budd purchased 12,000 shares of the company’s stock in a transaction on Thursday, December 19th. The shares were bought at an average price of $1.71 per share, for a total transaction of $20,520.00. Following the completion of the transaction, the director now directly owns 12,000 shares in the company, valued at $20,520. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock opened at $1.70 on Friday. The firm has a market cap of $69.49 million, a price-to-earnings ratio of -0.83 and a beta of 1.65. Vigil Neuroscience, Inc. has a 1 year low of $1.60 and a 1 year high of $6.06. The firm’s 50 day moving average price is $3.02 and its two-hundred day moving average price is $3.49.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds have recently modified their holdings of the stock. Acadian Asset Management LLC acquired a new position in shares of Vigil Neuroscience in the second quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Vigil Neuroscience in the 2nd quarter valued at approximately $87,000. Renaissance Technologies LLC boosted its stake in Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares during the period. Walleye Capital LLC grew its position in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after purchasing an additional 92,217 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in Vigil Neuroscience during the 3rd quarter valued at $442,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on VIGL shares. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Vigil Neuroscience in a report on Friday, November 8th. William Blair assumed coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an “outperform” rating on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Finally, Wedbush boosted their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $19.75.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.